Early detection and thus rapid therapy of cardiotoxicity related to chemotherapy are essential for restoring cardiovascular function. The complete recovery of the cardiovascular system decreases with time to identify the presence of cardiotoxic damage. The project aims to define new biomarkers for the early detection of cardiotoxicity in patients treated with chemotherapy.
The most effective approach to minimizing the consequences of cardiotoxicity of oncological treatment is its early identification, adjustment of oncological treatment (change of procedure, dose, drugs), and immediate initiation of cardiovascular therapy. However, the current standard for monitoring the cardiovascular system in cancer patients identifies cardiotoxicity only if functional impairment has already occurred, which precludes any chance of effective prevention. The aim of the project is to identify new biomarkers for the early detection of the cardiotoxic effect of chemotherapy in women with breast cancer.
Study Type
OBSERVATIONAL
Enrollment
200
Blood sample collection for mRNA determination
Echocardiography for detection of ventricular dysfunction
MRI for early detection of myocardial impairment caused by chemotherapy
Cardiology Prague Ltd
Prague, Czechia
RECRUITINGOncology Center Medicon
Prague, Czechia
RECRUITINGEarly detection of the cardiotoxic effect of chemotherapy using new biomarkers
Echocardiography and MRI detection of cardiotoxic effect of chemotherapy - dysfunction of left ventricle, arrythmias, hypertension
Time frame: one year follow-up.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Diagnostic test for detection of arrhythmias as a consequence of cardiotoxicity
Diagnostic test for detection of hypertension as a consequence of cardiotoxicity